Ventrix Initiates Clinical Trial of VentriGel™

Ventrix, Inc., today announced that it has initiated a Phase 1 trial of VentriGel™, an off-the-shelf, biomaterial scaffold designed to facilitate the repair of cardiac tissue following myocardial infarction (MI), commonly known as a heart attack.

The release as fetched from its publisher. ventrixbio.com ↗